Hemab Therapeutics Holdings, Inc. Common Stock
NASDAQ:COAGBiotechnology
+$2.32 today
- Market cap
- $1.83B
- Beta
- 0.00
Volume 0.30M
Average 0.34M
COAG Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Hemab Therapeutics Holdings, Inc. Common StockNASDAQ: COAG
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development of $20.34M in Q2 FY2026
Q2 FY2026 research & development was $20.34M.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 59.63M USD
- Year-over-year change
- —
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 59.63M | — |
Research & Development vs competitors
How COAG compares with its peers on the latest reported figures
- COAG's FY2025 research & development of $59.63M is the 4th highest of the 5 companies compared; the peer median is $157.95M.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
DMRADamora Therapeutics, Inc. | LTM Mar 2026 | $224.29M | +4762.0% | +61.0% | — |
IRONDisc Medicine, Inc. | LTM Sep 2026 | $183.14M | +22.7% | +72.2% | — |
| LTM Mar 2026 | $132.76M | -4.7% | -10.7% | 733.7% | |
COAGHemab Therapeutics Holdings, Inc. Common Stock | FY2025 | $59.63M | — | — | — |
| LTM Mar 2026 | $13.94M | -59.3% | -21.6% | 1624.7% | |
| Peer median (excluding COAG) | $157.95M | +9.0% | +25.1% | 1179.2% | |
Competitors are the stored peer set for COAG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2025 Dec 2025 |
|---|---|
| Revenue | 0 |
| Cost of Revenue | 0 |
| Gross Profit | 0 |
| Gross Margin | — |
| Research & Development | 59.63M |
| Selling, General & Admin | 10.49M |
| Operating Expenses | 70.12M |
| Depreciation & Amortization | 304K |
| EBITDA | (69.82M) |
| EBITDA Margin | — |
| Operating Income | (70.12M) |
| Operating Margin | — |
| Interest Income | 1.97M |
| Interest Expense | 0 |
| Other Income / Expenses | 5.98M |
| Income Before Tax | (64.14M) |
| Pre-Tax Margin | — |
| Income Tax Expense | (227K) |
| Net Income | (63.91M) |
| Net Margin | — |
| EPS (Basic) | (2.33) |
| EPS (Diluted) | (2.33) |
| Weighted Avg Shares | 27.44M |
| Weighted Avg Shares (Diluted) | 27.44M |
Hemab Therapeutics Holdings, Inc. Common Stock
NASDAQ:COAG
Intrinsic Alpha fair value
Locked
Current Price
$39.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.